ArticleEsophagus : official journal of the Japan Esophageal Society2026
Biodegradable and self-expanding metal stents in the treatment of children with strictures after esophageal atresia repair.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study compared the efficacy and complications of biodegradable stents (BDS) versus self-expandable fully covered metal stents (SEMS) in pediatric patients with strictures after esophageal atresia repair.
methodsThe charts of children with esophageal atresia (EA) undergoing stent treatment for anastomotic stricture were retrospectively reviewed. Primary outcomes included time to reintervention (TTR) and procedural success, defined as no necessity of further intervention with a patent esophageal lumen at the time of follow-up. Secondary outcomes included stent-related complications.
resultsFrom November 2016 to March 2024, a total of 22 BDS and 26 SEMS were placed in 15 patients for strictures. Median TTR was 77 days for BDS vs. 49 days for SEMS. BDS-treated patients had a 64% lower relapse risk (HR: 0.36, CI: 0.19-0.7, p < 0.003). At the end of individual follow-up (median: 6 months), exclusive stenting succeeded in 4 patients, stenting with other minimally invasive procedures in 2, and with surgery in 2. Migration (18.8%) was more less frequent with BDS compared to SEMS (OR: 0.11, CI: 0.00-0.97, p < 0.028), while there was a trend towards more granulation tissue formation with BDS (OR: 3.48, CI: 0.99-24.2, p = 0.052).
conclusionAlthough relapse occurs frequently in the long term, stenting may offer an alternative to assure esophageal patency in the medium term with only few and minor associated complications, notably stent migration and granulation tissue potentially causing restenosis. If placed for recalcitrant stricture, longer periods free of interventions are achieved in comparison to iterative dilatation, particularly when using BDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.